Aim
GHD
SECONDARY, GHD

To assess whether children in established puberty with early GHD reversal who stop growth hormone therapy (GH −) achieve no worse near final height standard deviation scores (FH SDS) (primary outcome), target height (TH) minus near final height (FH), health-related quality of life (HRQoL), bone health index and lipid profiles (secondary outcomes) than those continuing growth hormone (GH +).To determine the cost-effectiveness of GH − in the early re-testing scenario and the cost-effectiveness of the new care pathway (early re-testing) compared to traditional care (late re-testing).To assess staff, parent and patient perspectives of the trial pathways and reasons for declining to participate or dropping out of the trial.